Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone app and glucose sensor aim to boost weight loss

NCT ID NCT07395466

Symptom relief Sponsor: National University Health System, Singapore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a smartphone app called eTRIP, which uses artificial intelligence to help people with overweight or obesity make healthier food choices and stick to their weight loss goals. Some participants also wear a continuous glucose monitor for 10 days to see how their blood sugar responds to meals. The goal is to see if these tools help people lose weight and improve their eating habits over 10 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
behavioural intervention (eTRIP smartphone app and continuous glucose monitoring)
What this could lead to
If it works, this could offer a practical, tech-based tool to help people lose weight and improve eating habits.
What could go wrong
This is an early-stage study with no control group comparison for the app alone, and results may not apply to everyone. Weight loss can be hard to sustain long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. are 21-65 years old 2. have BMI ≥23 kg/m2 3. can comprehend the English language 4. uses a smartphone that can download apps 5. are willing to perform continuous glucose monitoring (CGM) using the Dexcom continuous glucose monitoring system 6. willing to travel to the National University of Singapore (NUS) 7. able to provide informed consent Exclusion Criteria: 1. are using/intend to use other apps for weight loss; 2. are pregnant or lactating (as it would affect weight change and caloric needs) 3. are diagnosed severe mental disorders (e.g. major depressive disorder and schizophrenia) 4. are on prescribed meal replacements or pharmacotherapy 5. have serious medical conditions 6. are scheduled for any kind of surgery within the next 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight and/or obesity Overweight or obese adults Overweight/obesity

Contacts and locations

Locations

  • National University of Singapore

    Singapore, 117597, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.